Table 3.

miRNA candidates correlated to anticancer treatment resistance to the drugs in the FOLFIRINOX and nab-paclitaxel/gemcitabine regimens in tissues and cells from solid tumors

Drug	miRNA	Expression/polymorphism	Tumor type	Ref.
5-FU	miR-21	Overexpression	Pancreatic cancer	Donahue et al[126], J Surg Oncol 2014
5-FU and irinotecan	pri-miR26a-1	rs7372209 polymorphism	Colorectal cancer	Boni et al[132], Pharmacogenomics J 2011
5-FU and oxaliplatin	miR-106a, miR-484, miR-130b	Overexpression	Colorectal cancer	Kjersem et al[143], Mol Oncol 2014
5-FU, paclitaxel and oxaliplatin	miR-27a	Overexpression	Gastric cancer	Huang et al[135], J Cell Biochem 2014
5-FU, capecitabine and oxaliplatin	miR-625-3p, miR-181b, miR-27b	Overexpression	Colorectal cancer	Rasmussen et al[133], Mol Oncol 2013
Irinotecan and cetuximab	miR-345	Overexpression	Colorectal cancer	Schou et al[144], PLoS One 2014
Oxaliplatin	miR-203	Overexpression	Colorectal cancer	Zhou et al[145], Mol Oncol 2014
Carboplatin and paclitaxel ± sorafenib	miR-659-3p	Downregulation	Melanoma	Villaruz et al[136], Clin Epigenetics 2015
Paclitaxel	miR-200c	Downregulation	Ovarian and endometrial cancer	Cochrane et al[146], Mol Cancer Ther 2009
Paclitaxel	miR-145	Downregulation	Ovarian cancer	Zhu et al[147], Int J Cancer 2014
Paclitaxel	miR-17-5p	Downregulation	Lung cancer	Aggarwal et al[148], Planta Med 2008
Gemcitabine	miR-21	Overexpression	Pancreatic cancer	Hwang et al[127], PLoS One 2010
				Giovannetti et al[128], Cancer Res 2010
				Caponi et al[129], Ann Oncol 2013
Gemcitabine	miR-21, miR-23a, miR-27a	Overexpression	Pancreatic cancer	Frampton et al[131], Gastroenterology 2014